Sirius XM Holdings Inc vs Twist Bioscience Corp — how do they compare? Sirius XM Holdings Inc trades at $28.71 (market cap $9.71B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Sirius XM Holdings Inc is the larger of the two by market cap, and Sirius XM Holdings Inc pays a 3.75% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| SIRI | TWST | |
|---|---|---|
Market Cap | $9.71B | $8.42B |
Sector | Media | Health |
52-Week High | $32.59 | $153.10 |
52-Week Low | $19.92 | $24.16 |
Enterprise Value | $18.99B | $8.35B |
Dividend Yield | 3.75% | — |
Signals from Pluang's Aura AI — not financial advice
Sirius XM Holdings (SIRI) trades at $28.80, down 0.66% today, with a bullish technical signal from moving averages and neutral oscillators. Recent earnings show mixed results, with Q1 2026 beating expectations but Q4 2025 and Q2 2026 missing. The company maintains solid profitability with a 10.23% net income margin and trades at a P/E of 11.57, below industry averages. Key developments include a YouTube partnership expected to boost EBITDA by $350–400 million by 2029, as reported by Seeking Alpha on September 8, 2026.
SIRI presents a value opportunity with undervalued metrics and analyst consensus pointing to 21% upside to the $34.86 price target. Risks include volatile earnings performance and high debt levels, though debt-to-asset ratios have improved from 94.31% in 2022 to 35.63% in 2025. Institutional interest is strong, with BlackRock and Deutsche Bank increasing stakes in Q2 2026 per SEC filings.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Trailing returns across standard periods
Latest headlines on both assets
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →